Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Immunoglobulin Light-chain Amyloidosis 3Pleural Effusion, Malignant 2Amyloidosis 2Tuberous Sclerosis 1Skin Toxicity 1Ras-wildtype Colorectal Cancer 1Polycystic Ovary Syndrome 1Pancreatic Neoplasms 1Pain 1Neoplasm Metastasis 1Menstruation Disturbances 1Lymphoma, Non-Hodgkin 1Lymphangioleiomyomatosis 1Intracranial Aneurysm 1Hyperandrogenism 1Hemangioma, Cavernous 1Head and Neck Neoplasms 1Exanthema 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Arteriovenous Malformations 1Amyloidosis, Familial 1Advanced Malignant Neoplasm 1AA amyloidosis 1

Interventions

dexpanthenol 1Triamcinolone Acetonide 1Tetracycline 1Provitamins 1Prednisone 1Panitumumab 1Minocycline 1Irinotecan 1IFL protocol 1Hydrocortisone 1Gels 1Erlotinib Hydrochloride 1Doxycycline 1Dapsone 1Clindamycin 1Anti-Bacterial Agents 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Exanthema × Doxycycline × Clear all
NCT02239731 2018-02-27

Safety, Tolerability and Efficacy Study of Doxycycline Foam for the Prevention of EGFRI Skin Toxicity in Cancer Patients

Vyne Therapeutics Inc.

Phase 2 Completed
24 enrolled

Exanthema

Data powered by HemOnc (CC BY 4.0) Colophon âš¡